2-(3-bromo-phenyl)-acetoacetonitrile | 30118-02-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-bromo-phenyl)-acetoacetonitrile
• 英文别名: 2-(3-Brom-phenyl)-acetoacetonitril；2-(3-bromo-phenyl)-3-oxo-butyronitrile；2-(3-Bromophenyl)-3-oxobutanenitrile
• CAS: 30118-02-6
• 化学式: C₁₀H₈BrNO
• 分子量: 238.084
• InChiKey: YNSRFDBOLZEERT-UHFFFAOYSA-N

物化性质

• 沸点：
  296.1±25.0 °C(Predicted)
• 密度：
  1.463±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(3-Bromophenyl)-3-oxobutanenitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(3-Bromophenyl)-3-oxobutanenitrile
CAS number: 30118-02-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H8BrNO
Molecular weight: 238.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(3-bromo-phenyl)-acetoacetonitrile 在 盐酸肼 作用下， 以 乙醇 为溶剂， 生成 4-(3-bromophenyl)-3-methyl-1H-pyrazol-5-amine
  参考文献：
  名称：

  N-Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK

  摘要：

  由于击中导向优化，氨基吡唑3a是一种选择性超过44种激酶的NIK抑制剂。

  DOI：

  10.1039/c8md00068a
• 作为产物：
  描述：

  3-溴氰苄 、 乙酸乙酯 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 0.08h， 生成 2-(3-bromo-phenyl)-acetoacetonitrile
  参考文献：
  名称：

  N-Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK

  摘要：

  由于击中导向优化，氨基吡唑3a是一种选择性超过44种激酶的NIK抑制剂。

  DOI：

  10.1039/c8md00068a

文献信息

• Enantioselective Construction of Aryl-Substituted All-Carbon Quaternary Stereocenters by Using Tertiary Amine-Thiourea-Catalyzed Michael Additions
  作者：Peng Chen、Xu Bao、Le-Fen Zhang、Guo-Jie Liu、Yi-Jun Jiang

  DOI：10.1002/ejoc.201501420

  日期：2016.2

  A catalytic enantioselective synthetic strategy for the aryl-substituted all-carbon quaternary stereocenters of bioactive hydrodibenzofuran alkaloids was achieved by the Michael addition reaction of α-cyano ketones and acrylates using a chiral tertiary amine–thiourea catalyst. This method can tolerate steric bulkiness and multiple functional groups, and 32 Michael adducts were prepared in good to excellent

  生物活性氢化二苯并呋喃生物碱的芳基取代的全碳季立体中心的催化对映选择性合成策略是通过使用手性叔胺-硫脲催化剂的 α-氰基酮和丙烯酸酯的迈克尔加成反应实现的。这种方法可以容忍空间体积和多个官能团，并且以良好到极好的收率制备了 32 种迈克尔加合物，并具有中等到良好的对映选择性。一次重结晶后，产物的对映体纯度也可以提高到 99% ee。这种对映选择性迈克尔加成具有低成本、无金属且易于操作的程序，可以提供四克规模的多功能对映纯迈克尔加合物，并为许多氢化二苯并呋喃天然产物提供足够数量的潜在前体。
• Organic compounds
  申请人：Bold Guido

  公开号：US20050222171A1

  公开（公告）日：2005-10-06

  The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.

  该发明涉及在激酶依赖性疾病的治疗中使用吡唑并[1,5a]嘧啶-7-基胺化合物及其盐，并用于制备用于治疗该类疾病的药物制剂，新型吡唑并[1,5a]嘧啶-7-基胺化合物，以及制备新型吡唑并[1,5a]嘧啶-7-基胺化合物的方法。
• Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders
  申请人：Sivasankaran Rajeev

  公开号：US20090069315A1

  公开（公告）日：2009-03-12

  The invention relates to methods of using the compounds of the invention, including pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor in a cell, stimulating neural regeneration, and reversing neuronal degeneration, by administering a compound of the invention to a cell or subject in an effective amount.

  该发明涉及使用该发明的化合物的方法，包括吡唑并[1,5a]嘧啶-7-基胺化合物及其盐，以及包含相同的药物组合物，在治疗Eph受体相关（例如神经）损伤和疾病方面的用途。该发明还涉及通过向细胞或受体中有效量的给予该发明的化合物，来调节Eph受体的活性，刺激神经再生，并逆转神经细胞的退化。
• [EN] PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES<br/>[FR] DERIVES DE PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DESTINES A ETRE UTILISES DANS LE TRAITEMENT DE MALADIES DEPENDANTES DE LA PROTEINE KINASE
  申请人：NOVARTIS AG

  公开号：WO2005070431A1

  公开（公告）日：2005-08-04

  The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.

  该发明涉及使用吡唑并[1,5a]嘧啶-7-基胺化合物及其盐来治疗激酶依赖性疾病，并用于制备用于治疗该疾病的制药制剂，新的吡唑并[1,5a]嘧啶-7-基胺化合物，以及制备新的吡唑并[1,5a]嘧啶-7-基胺化合物的方法。
• Aromatic amino acid hydroxylase inhibitors. I. Halogenated phenylalanines
  作者：Raymond E. Counsell、P. Desai、Terry Douglas Smith、Peter S. Chan、P. A. Weinhold、V. B. Rethy、D. Burke

  DOI：10.1021/jm00300a004

  日期：1970.11